文献速递肿瘤 PET/CT骨显像与常规 SPECT

FAPI-PET与FDG-PET在风湿性多肌痛和巨细胞动脉炎中的前瞻性对比研究

Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-04-23

该前瞻性研究纳入78例风湿性多肌痛(PMR)/巨细胞动脉炎(GCA)患者,分别接受FAPI-PET(27例)或FDG-PET(51例)显像,并与PMR-AS临床活动度评分相关分析。在PMR中,FAPI-PET对肩带区敏感性更高(91.3% vs 66.7%,P=0.02)、摄取强度更高(SUVmax 9.5 vs 5.6,P<0.01),且FAPI-PET视觉指数与PMR-AS强相关(R=0.751,P=0.0002),显著优于FDG-PET(R=0.312,P=0.0603)。在较小的GCA亚组中,FDG-PET对血管受累似乎更敏感。

要点

  • PMR中FAPI-PET肩带区敏感性91.3%优于FDG-PET的66.7%(P=0.02)。
  • FAPI-PET视觉指数与PMR-AS强相关(R=0.751),优于FDG-PET(R=0.312)。
  • GCA亚组中FDG-PET对血管受累似乎更敏感,但需更大样本验证。

核心结论

  • 在PMR中,FAPI-PET与临床疾病活动度的相关性优于FDG-PET,并呈现独特的显像模式。
  • 在较小的GCA亚组中,FDG-PET对血管受累似乎更敏感,但需更大研究确认。
  • FAPI-PET有望作为活动性PMR的影像生物标志物,可能改善诊断与表型分层。

研究设计与样本

  • 前瞻性对比研究,纳入78例PMR/GCA患者(FAPI-PET 27例,FDG-PET 51例)。
  • 采用2012 EULAR/ACR的PMR标准和2022 ACR/EULAR的GCA标准,诊断经中位9.2个月随访确认。
  • 所有患者在免疫抑制治疗前完成临床、实验室评估及PET/CT显像。
  • FAPI-PET视觉指数为受累部位视觉评分(0–3分)之和,并与PMR-AS及临床结局进行相关分析。

主要发现

  • 纯PMR占队列的83.3%。
  • PMR中,FAPI-PET对肩带区敏感性为91.3%,FDG-PET为66.7%(P=0.02)。
  • PMR中,FAPI-PET的SUVmax为9.5,FDG-PET为5.6(P<0.01)。
  • FDG-PET在坐骨结节等部位的检出率更高。
  • FAPI-PET视觉指数与PMR-AS强相关(R=0.751,P=0.0002),FDG-PET相关性为R=0.312(P=0.0603)。

关键数值与推荐

  • PMR诊断采用2012 EULAR/ACR标准,GCA诊断采用2022 ACR/EULAR标准。
  • FAPI-PET视觉指数由受累部位视觉评分(0–3分)求和得出。
  • 临床活动度采用PMR-AS评估,并与影像指标做相关分析。

临床怎么用

  • 在PMR患者中,FAPI-PET可能提供与临床活动度更相关的影像评估。
  • FDG-PET在GCA血管受累评估中可能仍具优势,但需更大样本验证。
  • FAPI-PET视觉指数或有助于活动性PMR的诊断与表型分层。

局限性

  • GCA亚组样本量较小,FDG-PET对血管受累更敏感的发现需更大研究确认。
  • FAPI-PET与FDG-PET为不同患者组比较(27例 vs 51例),非同一患者自身对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform a prospective comparative study of the novel FAPI-PET/CT with the established FDG-PET/CT for identifying characteristic inflammatory patterns in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). METHODS: In this prospective study, 78 patients (27 FAPI-PET, 51 FDG-PET) with PMR/GCA were enrolled using the 2012 EULAR/ACR criteria for PMR and the 2022 ACR/EULAR criteria for GCA, with diagnosis confirmed after a median 9.2-month follow-up. All underwent clinical and laboratory evaluation plus PET/CT imaging before any immunosuppressive treatment. The FAPI-PET Visual Index was derived by summing visual scores (0–3) across involved sites. Imaging findings were correlated with the PMR-AS and clinical outcomes. RESULTS: Pure PMR accounted for 83.3% of the cohort. In PMR, FAPI-PET showed superior sensitivity in the shoulder girdle (91.3% vs. 66.7%, P = 0.02) and higher uptake intensity (SUVmax 9.5 vs. 5.6, P < 0.01) versus FDG-PET, which showed higher detection at sites like the ischial tuberosities. Crucially, the FAPI-PET Visual Index correlated strongly with PMR-AS (R = 0.751, P = 0.0002), significantly outperforming FDG-PET (R = 0.312, P = 0.0603). In the smaller GCA subgroup, FDG-PET appeared more sensitive for vascular involvement. CONCLUSION: FAPI-PET demonstrates a distinct imaging profile and shows a superior correlation with clinical disease activity in PMR compared to FDG-PET in this comparative study. In the small subgroup of patients with GCA, FDG-PET appeared more sensitive for vascular involvement, but these findings require confirmation in larger studies. FAPI-PET shows promise as an imaging biomarker of active PMR, potentially improving diagnosis and phenotypic stratification.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Han X, He Y, Yang J, et al. Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42020812. doi:10.1007/s00259-026-07900-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。